Rhythm Pharmaceuticals Inc. (RYTM)
NASDAQ: RYTMHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 88.45 0.00%
RYTM stock chart
Technical analysisKey statistics
All statistics- Market cap
- $6.09B
- EPS (TTM)
- -$3.12
- Dividend yield
- None
- 52-week range
- 74.50 – 122.20
- Day range
- 88.23 – 91.37
- Volume / Avg
- 810.74K / 646.31K
- Beta
- —
- Shares outstanding
- 68.85M
- Next earnings
- Nov 3, 2026
52-week range
RYTM stock today
Shares of Rhythm Pharmaceuticals (RYTM) finished lower on Oct 7 at $88.45, a drop of 2.56% or $2.32 per share, versus the S&P 500's 0.22% decline. At this level, RYTM sits in the middle of its 52-week range of $74.50 to $122.20: 27.6% below the high, set on Dec 11, 2025 and 18.7% above the low. RYTM is down 16.5% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 10.5%.
Rhythm Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$3.12), so its P/E ratio is not meaningful. Rhythm Pharmaceuticals's next earnings report is expected on Nov 3, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Rhythm Pharmaceuticals
Company profileRhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. David P. Meeker M.D.
- Headquarters
- Boston, MA
- Employees
- 414
- IPO year
- 2017
- Website
- rhythmtx.com
Financial highlights
Full financialsIn fiscal 2025, Rhythm Pharmaceuticals generated $189.8 million in revenue, up 45.8% from fiscal 2024, its 5th consecutive year of revenue growth. Rhythm Pharmaceuticals reported a net loss of $196.5 million, compared with a loss of $260.6 million a year earlier. Gross margin was 89.7% (flat year over year) and operating margin -101.2%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $189.76M | $130.13M | $77.43M | $23.64M | $3.15M |
| Growth | +45.83% | +68.06% | +227.56% | +649.46% | — |
| Net income | $-196.54M | $-260.60M | $-184.68M | $-181.12M | $-69.61M |
| EPS (diluted) | $-3.11 | $-4.34 | $-3.20 | $-3.47 | $-1.40 |
Analyst forecast
ForecastConsensus (18 analysts)
none
Avg. price target
$138.59+56.69%
- Strong buy 5
- Buy 11
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 3, 2026
- EPS estimate
- $-0.68
- Last reported (Q2 2026)
- Aug 4, 2026
- EPS actual vs est.
- $-0.73 vs —
Rhythm Pharmaceuticals peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BLTEBelite Bio Inc ADR | 156.08 | +0.30% | $6.29B | vs RYTM |
| IMVTImmunovant Inc. | 32.04 | -0.22% | $6.62B | vs RYTM |
| IOVAIovance Biotherapeutics Inc. | 12.92 | -0.35% | $5.85B | vs RYTM |
| LGNDLigand Pharmaceuticals Incorporated | 293.26 | -1.24% | $5.85B | vs RYTM |
| KODKodiak Sciences Inc | 91.08 | -1.36% | $5.72B | vs RYTM |
| CGONCG Oncology Inc. | 62.38 | -1.98% | $5.53B | vs RYTM |
| SYRESpyre Therapeutics Inc. | 80.85 | +0.92% | $7.13B | vs RYTM |
| PTCTPTC Therapeutics Inc. | 63.23 | -0.74% | $5.28B | vs RYTM |
Indexes, lists and sector
Appears in lists
Rhythm Pharmaceuticals stock FAQ
What is Rhythm Pharmaceuticals's stock price today?
RYTM last traded at $88.45 as of Oct 7, 4:00 PM EDT, down 2.56% on the day. Prices are delayed at least 15 minutes.
When is Rhythm Pharmaceuticals's next earnings date?
Rhythm Pharmaceuticals is expected to report earnings on Tuesday, November 3, 2026. Analysts expect EPS of $-0.68.
Who is Rhythm Pharmaceuticals's CEO?
Dr. David P. Meeker M.D. is the chief executive officer of Rhythm Pharmaceuticals Inc., which has about 414 employees.
What is the RYTM 52-week high?
The 52-week high for RYTM is $122.20 and the 52-week low is $74.50. The stock is currently 27.6% below its high.